HIV Scientific Papers
Achieving virological control in pan-resistant HIV-1 infection: A case series
The Lancet Vol 77 Month March, 2022 11
HIV-1 Non-Group M Phenotypic Susceptibility to Ibalizumab
IV Push Administration of Ibalizumab: Pharmacokinetics, Safety, and Efficacy
Efficacy, pharmacokinetics, and safety over 48 weeks with ibalizumab-based therapy in treatment-experienced adults infected with HIV-1: a phase 2a study.
J Acquir Immune Defic Syndr.
Assessment of genotypic patterns associated with HIV-1 sensitivity to ibalizumab [abstract].
Reviews in Antiviral Therapy & Infectious Diseases.
7:27. Proceedings of the European Meeting on HIV & Hepatitis 2020.